NORTH AMERICA

Fideres has conducted over 150 event study reports and damages assessments for Section 10b and 11 cases in the US. We provide expert services at all stages of securities litigation from pre-filing damages reports to class certification and merits expert reports as well as settlement plan of allocations.  Our testifying experts have an extensive track record in share, ADRs, bonds and derivatives. Sample cases include:

AAA

  • Over 100 event studies and market efficiency analysis

  • AXIOM Holding securities litigation, US – Merits report, addressing market efficiency and statistically significant disclosure dates, 17-CV-4756 (JPC)

  • Tesla 10b(5) securities litigation, US – expert consulting appointment for class merits report, 3:18-cv-04865 / 3:18-cv-04865-EMC

  • Mylan 10b(5) securities litigation, US – expert consulting appointment for class merits report, 1:16-CV-07926 (JPO)

  • Euain Browne and Faisal Yasin v Horizons ETF Corp. securities litgation, Canada – economic report, assessing fraudulent conduct and damages to investors, CV-20-00646401-00CP

  • American Century securities litigation, US – expert consulting appointment to identify fraudulent statements made by the defendant, a mutual fund acting as a “closet indexer”, 3:21-cv-08625-CRB

  • Perrigo 10b(5) securities litigation, US – pre-filing expert consulting appointment to identify fraudulent misstatements made by the defendant, 2:19-cv-04900-MCA-LDW

  • Teva 10b(5) securities litigation, US – pre-filing expert consulting appointment to identify fraudulent misstatements made by the defendant, 3:17-cv-00558

  • Endo 10b(5) securities litigation, US – pre-filing expert consulting appointment to identify fraudulent misstatements made by the defendant, 2:17-cv-05114

  • Taro 10b(5) securities litigation, US – pre-filing expert consulting appointment to identify fraudulent misstatements made by the defendant, 1:16-cv-08318

  • Lannett 10b(5) securities litigation, US – pre-filing expert consulting appointment to identify fraudulent misstatements made by the defendant, 2:16-cv-05932

  • Impax 10b(5) Class Action Generic Drug Manufacturer Antitrust Analysis, US – 4:16-cv-06557-HSG